Clare Arnott

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 45

Top Topics

Atrial Fibrillation

Body Mass Index

Chronic Kidney Disease

Top Venues

Diabetes, obesity & metabolism

Journal of the American Heart Association

Hypertension (Dallas, Tex. : 1979)

European heart journal

This page only lists publications with an associated author ORCID identifier.

Publications

Robert A Fletcher, William G Herrington, Rajiv Agarwal, Kaitlin J Mayne, Clare Arnott, Meg J Jardine, Kenneth W Mahaffey, Vlado Perkovic, Natalie Staplin, David Collins Wheeler, Glenn M Chertow, Hiddo J Lambers Heerspink, Brendon L Neuen
Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials. Clinical journal of the American Society of Nephrology : CJASN (2024)
Jie Yu, Clare Arnott, Qiang Li, Gian Luca Di Tanna, Maoyi Tian, Liping Huang, Xuejun Yin, Xinyi Zhang, Sallie-Anne Pearson, Darwin R Labarthe, Paul Elliott, Lijing L Yan, Bo Zhou, Yangfeng Wu, Bruce C Neal
Secondary Analysis of the Salt Substitute and Stroke Study (SSaSS): Effects of Potassium-Enriched Salt on Cardiac Outcomes. Hypertension (Dallas, Tex. : 1979) (2024)
Kathryn Cardoza, Amy Kang, Brendan Smyth, Tae Won Yi, Carol Pollock, Rajiv Agarwal, George Bakris, David M Charytan, Dick de Zeeuw, David C Wheeler, Hong Zhang, Christopher P Cannon, Vlado Perkovic, Clare Arnott, Adeera Levin, Kenneth W Mahaffey
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial. Diabetes, obesity & metabolism 26 (9) (2024)
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S Bajaj, G B John Mancini, Norman C Wong, April E Hebert, Fernando G Ang, Wally Rapattoni, Brendon L Neuen, Clare Arnott, Vlado Perkovic, Kenneth W Mahaffey
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association 13 (3) (2024)
Jie Yu, Clare Arnott, Qiang Li, Gian Luca Di Tanna, Maoyi Tian, Liping Huang, Xuejun Yin, Xinyi Zhang, Sallie-Anne Pearson, Darwin R Labarthe, Paul Elliott, Lijing L Yan, Bo Zhou, Yangfeng Wu, Bruce C Neal
Secondary Analysis of the Salt Substitute and Stroke Study (SSaSS): Effects of Potassium-Enriched Salt on Cardiac Outcomes. Hypertension (Dallas, Tex. : 1979) 81 (5) (2024)
Akihiko Koshino, Hiddo J Lambers Heerspink, Niels Jongs, Sunil V Badve, Clare Arnott, Bruce Neal, Meg Jardine, Kenneth W Mahaffey, Carol A Pollock, Vlado Perkovic, Michael K Hansen, Stephan J L Bakker, Takashi Wada, Brendon L Neuen
Canagliflozin and iron metabolism in the CREDENCE trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)
Navdeep Tangri, Thomas W Ferguson, Ryan J Bamforth, Silvia J Leon, Clare Arnott, Kenneth W Mahaffey, Sradha Kotwal, Hiddo J Lambers Heerspink, Vlado Perkovic, Robert A Fletcher, Brendon L Neuen
Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial. Diabetes, obesity & metabolism 26 (8) (2024)
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S Bajaj, G B John Mancini, Norman C Wong, April E Hebert, Fernando G Ang, Wally Rapattoni, Brendon L Neuen, Clare Arnott, Vlado Perkovic, Kenneth W Mahaffey
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association 13 (3) (2024)
Robert A Fletcher, William G Herrington, Rajiv Agarwal, Kaitlin J Mayne, Clare Arnott, Meg J Jardine, Kenneth W Mahaffey, Vlado Perkovic, Natalie Staplin, David Collins Wheeler, Glenn M Chertow, Hiddo J Lambers Heerspink, Brendon L Neuen
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials. Clinical journal of the American Society of Nephrology : CJASN (2024)
Jie Yu, Clare Arnott, Qiang Li, Gian Luca Di Tanna, Maoyi Tian, Liping Huang, Xuejun Yin, Xinyi Zhang, Sallie-Anne Pearson, Darwin R Labarthe, Paul Elliott, Lijing L Yan, Bo Zhou, Yangfeng Wu, Bruce C Neal
Secondary Analysis of the Salt Substitute and Stroke Study (SSaSS): Effects of Potassium-Enriched Salt on Cardiac Outcomes. Hypertension (Dallas, Tex. : 1979) 81 (5) (2024)
Angela X Chen, Robert Fletcher, Brendon L Neuen, Bruce C Neal, Clare Arnott
An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes. Diabetes, obesity & metabolism (2024)
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S Bajaj, G B John Mancini, Norman C Wong, April E Hebert, Fernando G Ang, Wally Rapattoni, Brendon L Neuen, Clare Arnott, Vlado Perkovic, Kenneth W Mahaffey
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association 13 (3) (2024)
Navdeep Tangri, Thomas W Ferguson, Ryan J Bamforth, Silvia J Leon, Clare Arnott, Kenneth W Mahaffey, Sradha Kotwal, Hiddo J Lambers Heerspink, Vlado Perkovic, Robert A Fletcher, Brendon L Neuen
Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial. Diabetes, obesity & metabolism (2024)
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S Bajaj, G B John Mancini, Norman C Wong, April E Hebert, Fernando G Ang, Wally Rapattoni, Brendon L Neuen, Clare Arnott, Vlado Perkovic, Kenneth W Mahaffey
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association (2024)
Kathryn Cardoza, Amy Kang, Brendan Smyth, Tae Won Yi, Carol Pollock, Rajiv Agarwal, George Bakris, David M Charytan, Dick de Zeeuw, David C Wheeler, Hong Zhang, Christopher P Cannon, Vlado Perkovic, Clare Arnott, Adeera Levin, Kenneth W Mahaffey
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial. Diabetes, obesity & metabolism (2024)
Jie Yu, Clare Arnott, Qiang Li, Gian Luca Di Tanna, Maoyi Tian, Liping Huang, Xuejun Yin, Xinyi Zhang, Sallie-Anne Pearson, Darwin R Labarthe, Paul Elliott, Lijing L Yan, Bo Zhou, Yangfeng Wu, Bruce C Neal
Secondary Analysis of the Salt Substitute and Stroke Study (SSaSS): Effects of Potassium-Enriched Salt on Cardiac Outcomes. Hypertension (Dallas, Tex. : 1979) 81 (5) (2024)
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S Bajaj, G B John Mancini, Norman C Wong, April E Hebert, Fernando G Ang, Wally Rapattoni, Brendon L Neuen, Clare Arnott, Vlado Perkovic, Kenneth W Mahaffey
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association 13 (3) (2024)
Jie Yu, Arianne N Sweeting, Chris Gianacas, Lauren Houston, Vivian Lee, Robert A Fletcher, Vlado Perkovic, Qiang Li, Brendon L Neuen, Otavio Berwanger, Hiddo J Lambers Heerspink, Dick de Zeeuw, Clare Arnott
The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial. Diabetes, obesity & metabolism (2023)
Akihiko Koshino, Megumi Oshima, Clare Arnott, Robert A Fletcher, George L Bakris, Meg Jardine, Kenneth W Mahaffey, Vlado Perkovic, Carol Pollock, Hiddo J Lambers Heerspink, Brendon L Neuen
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Diabetes, obesity & metabolism (2023)
Tae Won Yi, Michelle M Y Wong, Brendon L Neuen, Clare Arnott, Paul Poirier, Jochen Seufert, April Slee, Wally Rapattoni, Fernando G Ang, David C Wheeler, Kenneth W Mahaffey, Vlado Perkovic, Adeera Levin
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: integrated analysis from the CANVAS Program and CREDENCE trial. Diabetes, obesity & metabolism (2023)
Sok Cin Tye, Megumi Oshima, Clare Arnott, Brendon L Neuen, Robert A Fletcher, Bruce C Neal, Hiddo J Lambers Heerspink
The importance of targeting multiple risk markers in patients with type 2 diabetes: A post-hoc study from the CANVAS programme. Diabetes, obesity & metabolism (2023)
Robert A Fletcher, Clare Arnott, Patrick Rockenschaub, Aletta Elisabeth Schutte, Lewis Carpenter, Muthiah Vaduganathan, Rajiv Agarwal, George L Bakris, Tara I-Hsin Chang, Hiddo J Lambers Heerspink, Meg J Jardine, Kenneth W Mahaffey, Bruce C Neal, Carol A Pollock, Min Jun, Anthony Rodgers, Vlado Perkovic, Brendon L Neuen
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials. Journal of the American Heart Association (2023)
Abhinav Sharma, Pedro Marques, Brendon L Neuen, Robert A Fletcher, April E Hebert, Wally Rapattoni, Fernando G Ang, Clare Arnott, Adeera Levin, Subodh Verma, Vlado Perkovic, Kenneth W Mahaffey
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial. Diabetes, obesity & metabolism (2023)
Michael A Tsoukas, Vincent Woo, Sheldon W Tobe, April Slee, Wally Rapattoni, Fernando G Ang, Jochen Seufert, Brendon L Neuen, Clare Arnott, Kenneth W Mahaffey, David C Wheeler
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS Program and CREDENCE. Diabetes, obesity & metabolism (2023)
Amy Kang, Brendan Smyth, Brendon L Neuen, Hiddo J Lambers Heerspink, Gian Luca Di Tanna, Hong Zhang, Clare Arnott, Carinna Hockham, Rajiv Agarwal, George L Bakris, David M Charytan, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, David C Wheeler, Kenneth W Mahaffey, Vlado Perkovic, Meg J Jardine
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials. Diabetes, obesity & metabolism (2023)
Brendon L Neuen, Hiddo J Lambers Heerspink, Priya Vart, Brian Lee Claggett, Robert A Fletcher, Clare Arnott, Juliana de Oliveira Costa, Michael O Falster, Sallie-Anne Pearson, Kenneth W Mahaffey, Bruce C Neal, Rajiv Agarwal, George L Bakris, Vlado Perkovic, Scott D Solomon, Muthiah Vaduganathan
Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation (2023)
Vikas S Sridhar, Brendon L Neuen, Robert A Fletcher, April Slee, Fernando G Ang, Wally Rapattoni, Clare Arnott, David Z I Cherney, Vlado Perkovic, David C Wheeler, Adeera Levin
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials. Diabetes, obesity & metabolism (2023)
Robert A Fletcher, Niels Jongs, Glenn M Chertow, John Joseph Valentine McMurray, Clare Arnott, Meg J Jardine, Kenneth W Mahaffey, Vlado Perkovic, Patrick Rockenschaub, Ellen Burgess, Ricardo Correa-Rotter, Robert D Toto, Muthiah Vaduganathan, David Collins Wheeler, Hiddo J Lambers Heerspink, Brendon L Neuen
Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials. Journal of the American Society of Nephrology : JASN (2023)
Akihiko Koshino, Megumi Oshima, Clare Arnott, Robert A Fletcher, George L Bakris, Meg Jardine, Kenneth W Mahaffey, Vlado Perkovic, Carol Pollock, Hiddo J Lambers Heerspink, Brendon L Neuen
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis of the CREDENCE trial. Diabetes, obesity & metabolism (2023)
Claire M Lawley, Clare Arnott, Gemma A Figtree
Reassurance for parents with children born via assisted reproductive technology or too soon to tell? European heart journal (2023)
Clare Arnott, Bruce C Neal
Good for your heart and safe for your toes - a patient-level meta-analysis of DAPA-HF and DELIVER. European heart journal (2023)
Sok Cin Tye, Megumi Oshima, Clare Arnott, Brendon L Neuen, Robert Fletcher, Bruce C Neal, Hiddo J Lambers Heerspink
The importance of targeting multiple risk markers in patients with type 2 diabetes: a post-hoc study from the CANVAS program. Diabetes, obesity & metabolism (2023)
Chao Li, Jie Yu, Carinna Hockham, Vlado Perkovic, Brendon L Neuen, Sunil V Badve, Lauren Houston, Vivian Y J Lee, Jennifer Y Barraclough, Robert A Fletcher, Kenneth W Mahaffey, Hiddo J Lambers Heerspink, Christopher P Cannon, Bruce C Neal, Clare Arnott
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. Diabetes, obesity & metabolism 24 (10) (2022)
Jing-Wei Li, Clare Arnott, Hiddo J Lambers Heerspink, Qiang Li MBiostat, Christopher P Cannon, David Collins Wheeler, David M Charytan, Jennifer Barraclough, Gemma A Figtree, Rajiv Agarwal, George L Bakris, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol A Pollock, Hong Zhang, Bernard Zinman, Kenneth W Mahaffey, Vlado Perkovic, Bruce C Neal, Meg J Jardine
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial. Journal of the American Heart Association 11 (16) (2022)
Jennifer Y Barraclough, Jie Yu, Gemma A Figtree, Vlado Perkovic, Hiddo J Lambers Heerspink, Brendon L Neuen, Christopher P Cannon, Kenneth W Mahaffey, Aletta Elisabeth Schutte, Bruce C Neal, Clare Arnott
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial. Diabetes, obesity & metabolism 24 (6) (2022)
Brendon L Neuen, Megumi Oshima, Rajiv Agarwal, Clare Arnott, David Z I Cherney, Robert Edwards, Anna Maria Langkilde, Kenneth W Mahaffey, Darren K McGuire, Bruce C Neal, Vlado Perkovic, Annpey Pong, Marc S Sabatine, Itamar Raz, Tadashi Toyama, Christoph Wanner, David Collins Wheeler, Stephen D Wiviott, Bernard Zinman, Hiddo J Lambers Heerspink
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation 145 (19) (2022)
Akihiko Koshino, Meir Schechter, Taha Sen, Priya Vart, Brendon L Neuen, Bruce C Neal, Clare Arnott, Vlado Perkovic, Paul M Ridker, Katherine R Tuttle, Michael K Hansen, Hiddo J Lambers Heerspink
Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS. Diabetes care 45 (11) (2022)
Taha Sen, Akihiko Koshino, Bruce C Neal, Maarten J Bijlsma, Clare Arnott, Jing-Wei Li, Michael K Hansen, Joachim H Ix, Hiddo J Lambers Heerspink
Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial. Diabetes, obesity & metabolism 24 (10) (2022)
Julio C Nunes, Jie Yu, Clare Arnott, Meg J Jardine, Vlado Perkovic, Kenneth W Mahaffey
Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program. Diabetes, obesity & metabolism 24 (12) (2022)
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, Rajiv Agarwal, Clare Arnott, George L Bakris, Christopher P Cannon, David M Charytan, Robert Edwards, Jose Luis Gorriz Teruel, Meg J Jardine, Adeera Levin, Bruce C Neal, Luca De Nicola, Carol A Pollock, Norman Rosenthal, David Collins Wheeler, Kenneth W Mahaffey, Hiddo J L Heerspink
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. European heart journal (2021)
Clare Arnott, Jing-Wei Li, Christopher P Cannon, Dick de Zeeuw, Brendon L Neuen, Hiddo J Lambers Heerspink, David M Charytan, Anubha Agarwal, Mark D Huffman, Gemma A Figtree, George L Bakris, Tara I-Hsin Chang, Kent Feng, Norman Rosenthal, Bernard Zinman, Meg J Jardine, Vlado Perkovic, Bruce C Neal, Kenneth W Mahaffey
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. Diabetes, obesity & metabolism 23 (7) (2021)
Clare Arnott, Yuli Huang, Brendon L Neuen, Gian Luca Di Tanna, Christopher P Cannon, Richard Oh, Robert Edwards, Mary Kavalam, Norman Rosenthal, Vlado Perkovic, Meg J Jardine, Kenneth Mahaffey, Bruce C Neal
The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial. Diabetes, obesity & metabolism 22 (10) (2020)
Brendon L Neuen, Clare Arnott, Vlado Perkovic, Gemma Figtree, Dick de Zeeuw, Greg Fulcher, Min Jun, Meg J Jardine, Sophia Zoungas, Carol Pollock, Kenneth W Mahaffey, Bruce C Neal, Hiddo J Lambers Heerspink
Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes. Diabetes, obesity & metabolism 23 (2) (2020)
Chao Li, Zien Zhou, Brendon L Neuen, Jie Yu, Yuli Huang, Tamara K Young, Jingwei Li, Lin Li, Vlado Perkovic, Meg J Jardine, Lisa Keay, Maria Markoulli, Norm Rosenthal, George Capuano, Yshai Yavin, Bruce C Neal, Clare Arnott
Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes, obesity & metabolism 23 (1) (2020)
Clare Arnott, Michael Nelson, Maria Alfaro Ramirez, Jon Hyett, Marianne Gale, Amanda Henry, David S Celermajer, Lee Taylor, Mark Woodward
Maternal cardiovascular risk after hypertensive disorder of pregnancy. Heart (British Cardiac Society) 106 (24) (2020)